Gout Treatment
Latin America · 1 shared keyword
Updated
Reviewed by Chandani Patel
Latin America Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$116.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $113.9 Mn | — | — |
| 2025 (base) | $122.7 Mn | +$8.8 Mn | — |
| 2026 (forecast) | $132.2 Mn | +$9.4 Mn | +7.7% |
| 2027 (forecast) | $142.3 Mn | +$10.2 Mn | +16% |
| 2028 (forecast) | $153.3 Mn | +$11.0 Mn | +24.9% |
| 2029 (forecast) | $165.1 Mn | +$11.8 Mn | +34.5% |
| 2030 (forecast) | $177.8 Mn | +$12.7 Mn | +44.9% |
| 2031 (forecast) | $191.5 Mn | +$13.7 Mn | +56.1% |
| 2032 (forecast) | $206.3 Mn | +$14.7 Mn | +68.1% |
| 2033 (forecast) | $222.1 Mn | +$15.9 Mn | +81% |
| 2034 (forecast) | $239.3 Mn | +$17.1 Mn | +95% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $122.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $239.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, indication and end user (see all) |
| Key players | Takeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin, Arthrosi Therapeutics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.
Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.
The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by ANVISA (Brazil)[1], ARCSA (Ecuador)[2], COFEPRIS (Mexico)[3], ANMAT (Argentina)[4], INVIMA (Colombia)[5] and ISP (Chile)[6]. How care is paid for in some of these countries: the SUS (Brazil)[7]; public care and IESS (Ecuador)[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)[9]; public care, obras sociales and prepaid plans (Argentina)[10]; social health insurance (EPS) (Colombia)[11]; and FONASA and ISAPREs (Chile)[12].
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] ANMAT. Checked 19 Nov 2026.
[5] INVIMA. Checked 19 Nov 2026.
[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.
[7] CONITEC. Checked 14 Nov 2026.
[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.
[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.
[12] FONASA. Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.
What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Latin America · 1 shared keyword
Latin America
Latin America
Latin America
Latin America
Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Medical Devices · Latin America